Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | CALCR | P30988 | 1/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | GRPR | P30550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608619 | 0.99 | NAA50 (0.49) | NAA50CAPN1NTSR1PLK1CTSD | |
| SCHEMBL30608630 | 0.97 | NAA50 (0.46) | NAA50CAPN1NTSR1PLK1CTSD | |
| SCHEMBL30608591 | 0.97 | NAA50 (0.46) | NAA50CAPN1NTSR1PLK1CTSD | |
| SCHEMBL30608595 | 0.97 | NAA50 (0.50) | NAA50CAPN1NTSR1PLK1CTSD | |
| SCHEMBL30608589 | 0.97 | CAPN1 (0.50) | NAA50CAPN1NTSR1PLK1CTSD | |
| SCHEMBL30608601 | 0.97 | NAA50 (0.51) | NAA50CAPN1NTSR1PLK1CTSD | |
| SCHEMBL30608576 | 0.96 | CAPN1 (0.49) | NAA50CAPN1NTSR1CTSBCRHR1 | |
| SCHEMBL30608629 | 0.96 | NAA50 (0.51) | NAA50CAPN1NTSR1PLK1APLNR | |
| SCHEMBL30608578 | 0.95 | NAA50 (0.49) | NAA50CAPN1NTSR1PLK1APLNR | |
| SCHEMBL30608587 | 0.95 | NAA50 (0.46) | NAA50CAPN1NTSR1PLK1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646232-A1 | VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY | Université de Genève (CH) | 2025-11-12 | — | — | EP | claimed |
| WO-2024146707-A1 | VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY | UNIVERSITÉ DE GENÈVE (CH) | 2024-07-11 | — | — | WO | claimed |
| EP-4646232-A1 | VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY | Université de Genève (CH) | 2025-11-12 | — | — | EP | disclosed |
| US-20250090637-A1 | METHODS OF INHIBITING CEREBRAL INFLAMMATION | UNIVERSITÉ DE GENÈVE (CH) | 2025-03-20 | — | — | US | disclosed |
| CN-112469429-B | Use of CCR5 inhibitors in cancer treatment | 奥立安生物技术瑞士有限责任公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-112469430-B | Method for inhibiting cerebral inflammation | 日内瓦大学 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024146707-A1 | VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY | UNIVERSITÉ DE GENÈVE (CH) | 2024-07-11 | — | — | WO | disclosed |
| EP-3813870-B1 | CCR5 INHIBITOR FOR USE IN TREATING CANCER | ORION Biotechnology Switzerland Sarl (CH) | 2023-11-15 | — | — | EP | disclosed |
| EP-3813869-B1 | CCR5 INHIBITOR FOR USE IN TREATING A NEUROINFLAMMATORY DISORDER THAT INVOLVES CEREBRAL INFLAMMATION | UNIV GENEVE (CH) | 2023-10-18 | — | — | EP | disclosed |